Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease

Circulation Research

Volumn 114, Issue 8, 2014, Pages 1311-1319

  Dobrev, Dobromir ^a   Wehrens, Xander H T ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

atrial fibrillation; heart failure; phosphorylation; ryanodine receptor type 2

Indexed keywords

ATRIAL FIBRILLATION; HEART FAILURE; PHOSPHORYLATION; RYANODINE RECEPTOR TYPE 2;

ANIMALS; ARRHYTHMIAS, CARDIAC; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84898875027     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.300568     Document Type: Article

References (108)

1. Wehrens XH, Lehnart SE, Marks AR. Ryanodine receptor-targeted anti-arrhythmic therapy. Ann N Y Acad Sci. 2005;1047:366-375.
2. 2+ leak in heart failure: mere observation or functional relevance? Cardiovasc Res. 2008;77:302-314.
3. Eschenhagen T. Is ryanodine receptor phosphorylation key to the fght or fight response and heart failure? J Clin Invest. 2010;120:4197-4203.
4. Bers DM. Ryanodine receptor S2808 phosphorylation in heart failure: smoking gun or red herring. Circ Res. 2012;110:796-799.
5. Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest. 2013;123:46-52.
6. Wehrens XH, Lehnart SE, Marks AR. Intracellular calcium release and cardiac disease. Annu Rev Physiol. 2005;67:69-98.
7. McCauley MD, Wehrens XH. Ryanodine receptor phosphorylation, calcium/calmodulin-dependent protein kinase II, and life-threatening ventricular arrhythmias. Trends Cardiovasc Med. 2011;21:48-51.
8. Meissner G. Molecular regulation of cardiac ryanodine receptor ion channel. Cell Calcium. 2004;35:621-628.
9. Heijman J, Dewenter M, El-Armouche A, Dobrev D. Function and regulation of serine/threonine phosphatases in the healthy and diseased heart. J Mol Cell Cardiol. 2013;64:90-98.
10. 2+/calmodulin- de-pendent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004;94:e61-e70.
11. Marx SO, Marks AR. Dysfunctional ryanodine receptors in the heart: new insights into complex cardiovascular diseases. J Mol Cell Cardiol. 2013;58:225-231.
12. Ather S, Respress JL, Li N, Wehrens XH. Alterations in ryanodine receptors and related proteins in heart failure. Biochim Biophys Acta. 2013;1832:2425-2431.
13. Witcher DR, Kovacs RJ, Schulman H, Cefali DC, Jones LR. Unique phos-phorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem. 1991;266:11144-11152.
14. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
15. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci USA. 2006;103:511-518.
16. Stange M, Xu L, Balshaw D, Yamaguchi N, Meissner G. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryano-dine receptor phosphorylation mutants. J Biol Chem. 2003;278:51693-51702.
17. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, Dura M, Chen BX, Marks AR. Role of chronic ryanodine receptor phos-phorylation in heart failure and β-adrenergic receptor blockade in mice. J Clin Invest. 2010;120:4375-4387.
18. Benkusky NA, Weber CS, Scherman JA, Farrell EF, Hacker TA, John MC, Powers PA, Valdivia HH. Intact beta-adrenergic response and unmodifed progression toward heart failure in mice with genetic ablation of a major protein kinase A phosphorylation site in the cardiac ryanodine receptor. Circ Res. 2007;101:819-829.
19. Li Y, Kranias EG, Mignery GA, Bers DM. Protein kinase A phosphoryla-tion of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res. 2002;90:309-316.
20. Shan J, Kushnir A, Betzenhauser MJ, Reiken S, Li J, Lehnart SE, Lindegger N, Mongillo M, Mohler PJ, Marks AR. Phosphorylation of the ryanodine receptor mediates the cardiac fght or fight response in mice. J Clin Invest. 2010;120:4388-4398.
21. MacDonnell SM, García-Rivas G, Scherman JA, Kubo H, Chen X, Valdivia H, Houser SR. Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808. Circ Res. 2008;102:e65-e72.
22. Zhang H, Makarewich CA, Kubo H, Wang W, Duran JM, Li Y, Berretta RM, Koch WJ, Chen X, Gao E, Valdivia HH, Houser SR. Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res. 2012;110:831-840.
23. Carter S, Colyer J, Sitsapesan R. Maximum phosphorylation of the cardiac ryanodine receptor at serine-2809 by protein kinase A produces unique modifcations to channel gating and conductance not observed at lower levels of phosphorylation. Circ Res. 2006;98:1506-1513.
24. 2+ release [published online ahead of print February 24, 2014]. J Physiol. http://dx.doi.org/10.1113/jphysiol.2013.264689. Accessed February 24, 2014.
25. 2+ sensitivity. J Mol Cell Cardiol. 2012;53:33-42.
26. Sarma S, Li N, van Oort RJ, Reynolds C, Skapura DG, Wehrens XH. Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy. Proc Natl Acad Sci USA. 2010;107:13165-13170.
27. 2+ release are prevented by inactivation of G(alpha)11 and G(alpha)q in murine cardiomyocytes. Mol Cell Biochem. 2010;341:235-244.
28. 2+-handling protein profle in obese rats. Hypertension. 2010;56:629-635.
29. 2+ infux. Biochem Pharmacol. 2012;84:1024-1035.
30. Jeyaraj D, Haldar SM, Wan X, et al. Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature. 2012;483:96-99.
31. Gamble KL, Ciarleglio CM. Ryanodine receptors are regulated by the circadian clock and implicated in gating photic entrainment. J Neurosci. 2009;29:11717-11719.
32. van Oort RJ, McCauley MD, Dixit SS, Pereira L, Yang Y, Respress JL, Wang Q, De Almeida AC, Skapura DG, Anderson ME, Bers DM, Wehrens XH. Ryanodine receptor phosphorylation by calcium/calmodulin-depen-dent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation. 2010;122:2669-2679.
33. Respress JL, van Oort RJ, Li N, et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res. 2012;110:1474-1483.
34. Kushnir A, Shan J, Betzenhauser MJ, Reiken S, Marks AR. Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc Natl Acad Sci USA. 2010;107:10274-10279.
35. Said M, Becerra R, Valverde CA, Kaetzel MA, Dedman JR, Mundiña-Weilenmann C, Wehrens XH, Vittone L, Mattiazzi A. Calcium-calmodulin dependent protein kinase II (CaMKII): a main signal responsible for early reperfusion arrhythmias. J Mol Cell Cardiol. 2011;51:936-944.
36. Ather S, Wang W, Wang Q, Li N, Anderson ME, Wehrens XH. Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy. Heart Rhythm. 2013;10:592-599.
37. Chu DK, Jordan MC, Kim JK, Couto MA, Roos KP. Comparing isofu-rane with tribromoethanol anesthesia for echocardiographic phenotyping of transgenic mice. J Am Assoc Lab Anim Sci. 2006;45:8-13.
38. Constantinides C, Mean R, Janssen BJ. Effects of isofurane anesthesia on the cardiovascular function of the C57BL/6 mouse. ILAR J. 2011;52:e21-e31.
39. Rodriguez P, Bhogal MS, Colyer J. Stoichiometric phosphorylation of cardiac ryanodine receptor on serine 2809 by calmodulin-dependent kinase II and protein kinase A. J Biol Chem. 2003;278:38593-38600.
40. Santiago DJ, Curran JW, Bers DM, Lederer WJ, Stern MD, Ríos E, Shannon TR. Ca sparks do not explain all ryanodine receptor-mediated SR Ca leak in mouse ventricular myocytes. Biophys J. 2010;98:2111-2120.
41. 2+ leak promotes atrial fbrillation in mice. J Clin Invest. 2009;119:1940-1951.
42. Sood S, Chelu MG, van Oort RJ, Skapura D, Santonastasi M, Dobrev D, Wehrens XH. Intracellular calcium leak due to FKBP12.6 defciency in mice facilitates the inducibility of atrial fbrillation. Heart Rhythm. 2008;5:1047-1054.
43. 2+/calmodulin- dependent protein kinase II triggers atrial fbrillation. Circulation. 2013;128:1748-1757.
44. Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XH, Nattel S, Dobrev D. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fbrillation. Circulation. 2014;129:145-156.
45. Xie W, Santulli G, Guo X, Gao M, Chen BX, Marks AR. Imaging atri-al arrhythmic intracellular calcium in intact heart. J Mol Cell Cardiol. 2013;64:120-123.
46. Huke S, Bers DM. Ryanodine receptor phosphorylation at Serine 2030, 2808 and 2814 in rat cardiomyocytes. Biochem Biophys Res Commun. 2008;376:80-85.
47. 2+ concentration. Methods Mol Biol. 2013;937:239-251.
48. Silvestro AM, Ashley RH. Solubilization, partial purifcation and functional reconstitution of a sheep brain endoplasmic reticulum anion channel. Int J Biochem. 1994;26:1129-1138.
49. Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, Matecki S, Marks AR, Lacampagne A. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2010;107:1559-1564.
50. Kushnir A, Betzenhauser MJ, Marks AR. Ryanodine receptor studies using genetically engineered mice. FEBS Lett. 2010;584:1956-1965.
51. Picht E, Zima AV, Blatter LA, Bers DM. SparkMaster: automated calcium spark analysis with ImageJ. Am J Physiol Cell Physiol. 2007;293:C1073-C1081.
52. 2+ signalling. Eur J Pharmacol. 2013;700:181-193.
53. Valdivia HH. Ryanodine receptor phosphorylation and heart failure: phasing out S2808 and "criminalizing" S2814. Circ Res. 2012;110:1398-1402.
54. 2+ release. Circ Res. 2003;92:904-911.
55. 2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest. 2009;119:1230-1240.
56. Xiao B, Zhong G, Obayashi M, Yang D, Chen K, Walsh MP, Shimoni Y, Cheng H, Ter Keurs H, Chen SR. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts. Biochem J. 2006;396:7-16.
57. Marks AR, Marx SO, Reiken S. Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers. Trends Cardiovasc Med. 2002;12:166-170.
58. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, Jindal HK, Rochira JA, Kunitomo Y, Abdellatif M, Carnes CA, Elton TS, Györke S, Terentyev D. MicroRNA-1 and-133 increase arrhythmo-genesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One. 2011;6:e28324.
59. 2+ release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res. 2009;104:514-521.
60. Dodge-Kafka KL, Bauman A, Mayer N, Henson E, Heredia L, Ahn J, McAvoy T, Nairn AC, Kapiloff MS. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specifc phosphodiesterase PDE4D3. J Biol Chem. 2010;285:11078-11086.
61. Terentyev D, Viatchenko-Karpinski S, Gyorke I, Terentyeva R, Gyorke S. Protein phosphatases decrease sarcoplasmic reticulum calcium content by stimulating calcium release in cardiac myocytes. J Physiol. 2003;552:109-118.
62. El-Armouche A, Wittköpper K, Degenhardt F, Weinberger F, Didié M, Melnychenko I, Grimm M, Peeck M, Zimmermann WH, Unsöld B, Hasenfuss G, Dobrev D, Eschenhagen T. Phosphatase inhibitor-1-defcient mice are protected from catecholamine-induced arrhythmias and myocar-dial hypertrophy. Cardiovasc Res. 2008;80:396-406.
63. 2+ leak in intact ventricular myocytes from rabbits in heart failure. Circ Res. 2003;93:592-594.
64. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, Xie W, Shiomi T, Zalk R, Lacampagne A, Marks AR. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 2011;14:196-207.
65. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, Bers DM. Diabetic hyperglycae-mia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013;502:372-376.
66. Gonzalez DR, Treuer AV, Castellanos J, Dulce RA, Hare JM. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem. 2010;285:28938-28945.
67. Obayashi M, Xiao B, Stuyvers BD, Davidoff AW, Mei J, Chen SR, ter Keurs HE. Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. Cardiovasc Res. 2006;69:140-151.
68. 2+ leak in human cardiac pathology. Circulation. 2013;128:970-981.
69. 2+ leak in heart failure. Circ Res. 2005;97:1314-1322.
70. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, Brown JH. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003;92:912-919.
71. Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005;11:409-417.
72. Curran J, Tang L, Roof SR, Velmurugan S, Millard A, Shonts S, Wang H, Santiago D, Ahmad U, Perryman M, Bers DM, Mohler PJ, Ziolo MT, Shannon TR. Nitric oxide-dependent activation of CaMKII increases dia-stolic sarcoplasmic reticulum calcium release in cardiac myocytes in response to adrenergic stimulation. PLoS One. 2014;9:e87495.
73. He BJ, Joiner ML, Singh MV, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med. 2011;17:1610-1618.
74. Farr MA, Basson CT. Sparking the failing heart. N Engl J Med. 2004;351:185-187.
75. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med. 2004;14:61-66.
76. Wu Y, Temple J, Zhang R, Dzhura I, Zhang W, Trimble R, Roden DM, Passier R, Olson EN, Colbran RJ, Anderson ME. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation. 2002;106:1288-1293.
77. 2+ leak and arrhythmia. Circulation. 2013;127:913-922.
78. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196-200.
79. Marks AR, Priori S, Memmi M, Kontula K, Laitinen PJ. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminer-gic polymorphic ventricular tachycardia. J Cell Physiol. 2002;190:1-6.
80. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001;103:485-490.
81. 2+ handling and arrhythmogenesis. Circ Res. 2011;108:871-883.
82. Reiken S, Gaburjakova M, Gaburjakova J, He Kl KL, Prieto A, Becker E, Yi Gh GH, Wang J, Burkhoff D, Marks AR. beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation. 2001;104:2843-2848.
83. McCauley MD, Wehrens XH. Targeting ryanodine receptors for anti-arrhythmic therapy. Acta Pharmacol Sin. 2011;32:749-757.
84. Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 defciency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003;113:829-840.
85. Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, Landry DW, Kontula K, Swan H, Marks AR. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation. 2004;109:3208-3214.
86. Meli AC, Refaat MM, Dura M, Reiken S, Wronska A, Wojciak J, Carroll J, Scheinman MM, Marks AR. A novel ryanodine receptor mutation linked to sudden death increases sensitivity to cytosolic calcium. Circ Res. 2011;109:281-290.
87. 2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res. 2005;97:1173-1181.
88. Uchinoumi H, Yano M, Suetomi T, Ono M, Xu X, Tateishi H, Oda T, Okuda S, Doi M, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res. 2010;106:1413-1424.
89. 2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res. 2010;87:50-59.
90. 2+ activation in the cardiac ryanodine receptor is associated with ventricular fbrilla-tion and sudden death. Proc Natl Acad Sci USA. 2007;104:18309-18314.
91. Loaiza R, Benkusky NA, Powers PP, Hacker T, Noujaim S, Ackerman MJ, Jalife J, Valdivia HH. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2013;112:298-308.
92. Kannankeril PJ, Mitchell BM, Goonasekera SA, et al. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci USA. 2006;103:12179-12184.
93. Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Wronska A, Marks AR. Calcium leak through ryanodine receptors leads to atrial fbrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2012;111:708-717.
94. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fbrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62-73.
95. Hove-Madsen L, Llach A, Bayes-Genís A, Roura S, Rodriguez Font E, Arís A, Cinca J. Atrial fbrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myo-cytes. Circulation. 2004;110:1358-1363.
96. Vest JA, Wehrens XH, Reiken SR, Lehnart SE, Dobrev D, Chandra P, Danilo P, Ravens U, Rosen MR, Marks AR. Defective cardiac ryanodine receptor regulation during atrial fbrillation. Circulation. 2005;111:2025-2032.
97. 2+ handling in human chronic atrial fbrillation. Circulation. 2006;114:670-680.
98. 2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fbril-lation. Circulation. 2012;125:2059-2070.
99. Li N, Wang T, Wang W, Cutler MJ, Wang Q, Voigt N, Rosenbaum DS, Dobrev D, Wehrens XH. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fbrillation in FKBP12.6 knockout mice. Circ Res. 2012;110:465-470.
100. Beavers DL, Wang W, Ather S, Voigt N, Garbino A, Dixit SS, Landstrom AP, Li N, Wang Q, Olivotto I, Dobrev D, Ackerman MJ, Wehrens XH. Mutation E169K in junctophilin-2 causes atrial fbrillation due to impaired RyR2 stabilization. J Am Coll Cardiol. 2013;62:2010-2019.
101. 2+ leak and re-entry? Acta Physiol (Oxf). 2013;207:208-211.
102. 2+ levels in right atrial myocardium of patients with atrial fbrillation. Circ Res. 2010;106: 1134-1144.
103. Wittköpper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest. 2010;120:617-626.
104. Greiser M, Neuberger HR, Harks E, El-Armouche A, Boknik P, de Haan S, Verheyen F, Verheule S, Schmitz W, Ravens U, Nattel S, Allessie MA, Dobrev D, Schotten U. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fbrillation. J Mol Cell Cardiol. 2009;46:385-394.
105. Kirchhof P, Marijon E, Fabritz L, et al. Overexpression of cAMP-response element modulator causes abnormal growth and development of the atri-al myocardium resulting in a substrate for sustained atrial fbrillation in mice. Int J Cardiol. 2013;166:366-374.
106. Li N, Chiang DY, Wang S, et al. Ryanodine-receptor mediated calcium leak drives progressive development of an atrial fbrillation substrate in a transgenic mouse model. Circulation. 2014;129:1276-1285.
107. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004;304:292-296.
108. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380-383.